Top

Neurological Sciences

Published in:

01-02-2021 | Dementia | Original Article

Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Authors: Yoon-Sang Oh, Jean Hee Kim, Sang-Won Yoo, Eo-Jin Hwang, Chul Hyoung Lyoo, Kwang-Soo Lee, Joong-Seok Kim

Published in: Neurological Sciences | Issue 2/2021

Abstract

Background and objective

Neuropsychiatric symptoms are relatively common in Parkinson’s disease (PD). Many studies have revealed that striatal monoamine availability is associated with specific neuropsychiatric symptoms. This study was aimed to investigate the association between comprehensive neuropsychiatric symptoms and striatal monoamine availability in patients with early PD without dementia.

Methods

A total of 156 newly diagnosed patients with PD without dementia were included. All patients’ mental and behavioral problems were assessed with the 12-item Neuropsychiatric Inventory (NPI). They underwent positron emission tomography (PET) with ¹⁸F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane and brain magnetic resonance imaging (MRI). Patients were divided into no neuropsychiatric symptoms and neuropsychiatric symptoms groups according to total NPI score. After normalizing the PET images to spatially normalized MRI, regional standardized uptake value ratios (SUVRs) with a volume of interest template were analyzed for the two groups.

Results

Ninety-eight patients had more than one neuropsychiatric symptom. The SUVR of the thalamus in neuropsychiatric symptoms group was significantly lower than the SUVR in no neuropsychiatric symptoms group independent of age, sex, disease duration, or severity of motor symptoms.

Conclusion

Patients with early PD who have neuropsychiatric symptoms had a lower monoamine availability in the thalamus than those with no neuropsychiatric symptoms. This finding suggests that decreased monoamine transporter availability in the thalamus may be an imaging biomarker of neuropsychiatric symptoms in patients with PD.

Available only for authorised users

Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 80(8):928–930. https://doi.org/10.1136/jnnp.2008.166959CrossRefPubMed

Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 67(4):492–496. https://doi.org/10.1136/jnnp.67.4.492CrossRefPubMedPubMedCentral

Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007) Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78(1):36–42. https://doi.org/10.1136/jnnp.2005.083113CrossRefPubMed

Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A, Trapecio Group Study (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896. https://doi.org/10.1002/mds.22246CrossRefPubMed

Wen MC, Chan LL, Tan LC, Tan EK (2016) Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol 23(6):1001–1019. https://doi.org/10.1111/ene.13002.CrossRefPubMed

Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P (2012) Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord 18(9):1034–1038. https://doi.org/10.1016/j.parkreldis.2012.05.022CrossRefPubMed

Vriend C, Raijmakers P, Veltman DJ, van Dijk KD, van der Werf YD, Foncke EM, Smit JH, Berendse HW, van den Heuvel OA (2014) Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 85(2):159–164. https://doi.org/10.1136/jnnp-2012-304,811CrossRefPubMed

Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, Bruno I, Janiri L, Giordano A, Fasano A (2012) Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 39(12):1937–1948. https://doi.org/10.1007/s00259-012-2232-7CrossRefPubMed

Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappata S (2015) Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson’s disease patients. Parkinsonism Relat Disord 21(5):489–493. https://doi.org/10.1016/j.parkreldis.2015.02.015CrossRefPubMed

10.

Park SB, Kwon KY, Lee JY, Im K, Sunwoo JS, Lee KB, Roh H, Ahn MY, Park S, Kim SJ, Oh JS, Kim JS (2019) Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson’s disease: a detailed PET analysis of 12 striatal subregions. Neurol Sci 40(2):311–317. https://doi.org/10.1007/s10072-018-3632-7CrossRefPubMed

11.

Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Kapucu OL, Kluge A, Ziebell M, Darcourt J, Nobili F, Pagani M, Hesse S, Vander Borght T, Van Laere K, Tatsch K, la Fougère C (2014) Extrastriatal binding of [(1)(2)(3)I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging 41(10):1938–1946. doi: https://doi.org/10.1007/s00259-014-2785-8.

12.

Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752. https://doi.org/10.1136/jnnp.51.6.745CrossRefPubMedPubMedCentral

13.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424CrossRef

14.

Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, Na DL (2010) Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. J Korean Med Sci 25(7):1071–1076. https://doi.org/10.3346/jkms.2010.25.7.1071CrossRefPubMedPubMedCentral

15.

Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356. https://doi.org/10.1002/mds.24893CrossRefPubMedPubMedCentral

16.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707. https://doi.org/10.1002/mds.21507CrossRefPubMed

17.

Kim JS, Cho H, Choi JY, Lee SH, Ryu YH, Lyoo CH, Lee MS (2015) Feasibility of computed tomography-guided methods for spatial normalization of dopamine transporter positron emission tomography image. PLoS One 10(7):e0132585. https://doi.org/10.1371/journal.pone.0132585CrossRefPubMedPubMedCentral

18.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Parkinson’s Progression Markers Initiative (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 30(7):919–927. https://doi.org/10.1002/mds.26170CrossRefPubMedPubMedCentral

19.

Getz SJ, Levin B (2017) Cognitive and neuropsychiatric features of early Parkinson’s disease. Arch Clin Neuropsychol 32(7):769–785. https://doi.org/10.1093/arclin/acx091CrossRefPubMed

20.

Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(6):1314–1322. https://doi.org/10.1093/brain/awh445CrossRefPubMed

21.

Felicio AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, Silva SM, Amaro-Junior E, Andrade LA, Ferraz HB, Bressan RA (2010) Higher dopamine transporter density in Parkinson’s disease patients with depression. Psychopharmacology (Berl) 211(1):27–31. https://doi.org/10.1007/s00213-010-1867-yCrossRef

22.

Yoo SW, Oh YS, Hwang EJ, Ryu DW, Lee KS, Lyoo CH, Kim JS (2019) “Depressed” caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson’s disease. Neurobiol Dis. 132:104563. https://doi.org/10.1016/j.nbd.2019.104563CrossRefPubMed

23.

Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, Volterrani D, Bonuccelli U (2013) Mild affective symptoms in de novo Parkinson’s disease patients: relationship with dopaminergic dysfunction. Eur J Neurol 20(3):480–485. https://doi.org/10.1111/j.1468-1331.2012.03878.xCrossRefPubMed

24.

Joling M, van den Heuvel OA, Berendse HW, Booij J, Vriend C (2018) Serotonin transporter binding and anxiety symptoms in Parkinson’s disease. J Neurol Neurosurg Psychiatry 89(1):89–94. https://doi.org/10.1136/jnnp-2017-316,193.CrossRefPubMed

25.

Picillo M, Santangelo G, Erro R, Cozzolino A, Amboni M, Vitale C, Barone P, Pellecchia MT (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson’s disease. Parkinsonism Relat Disord 37:106–110. https://doi.org/10.1016/j.parkreldis.2017.02.010CrossRefPubMed

26.

Price JL, Drevets WC (2010) Neurocircuitry of mood disorders. Neuropsychopharmacology 35(1):192–216. https://doi.org/10.1038/npp.2009.104CrossRefPubMed

27.

Spies M, Knudsen GM, Lanzenberger R, Kasper S (2015) The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry 2(8):743–755. https://doi.org/10.1016/S2215-0366(15)00232-1CrossRefPubMed

28.

Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P (2010) Staging of serotonergic dysfunction in Parkinson’s disease: an in vivo 11C-DASB PET study. Neurobiol Dis 40(1):216–221. https://doi.org/10.1016/j.nbd.2010.05.028CrossRefPubMed

29.

Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O (2011) Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter. J Neurol 258(1):19–26. https://doi.org/10.1007/s00415-010-5666-5CrossRefPubMed

30.

Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, Le Bars D, Schmitt E, Bichon A, Pelissier P, Fraix V, Castrioto A, Sgambato-Faure V, Broussolle E, Tremblay L, Thobois S (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139(9):2486–2502. https://doi.org/10.1093/brain/aww162.CrossRefPubMed

31.

Monastero R, Di Fiore P, Ventimiglia GD, Camarda R, Camarda C (2013) The neuropsychiatric profile of Parkinson’s disease subjects with and without mild cognitive impairment. J Neural Transm (Vienna) 120(4):607–611. https://doi.org/10.1007/s00702-013-0988-y.CrossRef

32.

Leroi I, Pantula H, McDonald K, Harbishettar V (2012) Neuropsychiatric symptoms in Parkinson’s disease with mild cognitive impairment and dementia. Parkinsons Dis 2012:308097. https://doi.org/10.1155/2012/308097CrossRefPubMedPubMedCentral

Title: Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia
Authors: Yoon-Sang Oh
Jean Hee Kim
Sang-Won Yoo
Eo-Jin Hwang
Chul Hyoung Lyoo
Kwang-Soo Lee
Joong-Seok Kim
Publication date: 01-02-2021
Publisher: Springer International Publishing
Keywords: Dementia
Positron Emission Tomography
Parkinson's Disease
Dementia
Mild Cognitive Impairment
Published in: Neurological Sciences / Issue 2/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04859-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia

Abstract

Background and objective

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Arterial spin labeling hyperperfusion in seizures associated with non-ketotic hyperglycaemia: is it merely a post-ictal phenomenon?

Hyperkinetic manifestations in superficial siderosis: evidence for pathogenic network disruption

Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review

Changed pattern of hospital admission in stroke during COVID-19 pandemic period in Iran: a retrospective study

Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome

Ethical considerations in neurology during the COVID-19 pandemic